This Portal is the secure website to exchange information between Settling States and Participating Subdivisions/Participating Special Districts (Teva and Allergan) (collectively, “Beneficiaries”) and the Directing Administrator of the seven nationwide settlement agreements that resolve all opioid litigation brought by state and local governments against McKesson, Cardinal Health and AmerisourceBergen (“Distributors”), Janssen Pharmaceuticals, Inc. (“Janssen”), Allergan Finance, LLC and Allergan Limited (“Allergan”), Teva Pharmaceutical Industries Ltd. (“Teva”), Walmart Inc. (“Walmart”), CVS Health Corporation and CVS Pharmacy (“CVS”), and Walgreens Co. (“Walgreens”). The Settlement Agreements can be viewed online here. Only persons authorized by the Directing Administrator may use this Portal.

The first time you use your Portal, you are required to agree to the National Opioid Settlements Portal Account Holder Agreement. You must adhere to those terms. Unauthorized use of this system is prohibited. Violators may be subject to civil and criminal prosecution. All transactions are monitored by the Directing Administrator.

Pursuant to Section V.B.2 of the Distributor Settlement Agreement, Section VI.B.2 of the Janssen Settlement Agreement, Section VIII.C of the Allergan Public Global Opioid Settlement Agreement, Section VIII.C of the Teva Global Opioid Settlement Agreement, Section V.B of the Walmart Settlement Agreement, Section V.B of the CVS Settlement Agreement, and Section V.B of the Walgreens Settlement Agreement, (“Settlement Agreements”), if a Settling State or a Participating Subdivision/ Participating Special District uses any monies from the Settlement Fund(s) for a purpose that does not qualify as Opioid Remediation, the Settling State or Participating Subdivision shall identify such amounts and report how such funds were used, including if used to pay attorneys’ fees, investigation costs, litigation costs, or costs related to the operation and enforcement. If you are a Settling State or Participating Subdivision submitting the Non-Opioid Remediation Use Report, enter your credentials in the Login field on this page to access your Portal. If you do not have a Portal account, you can send a completed Non-Opioid Remediation Use Report to NonOpioidRemediationUseReporting@nationalopioidofficialsettlement.com.

The Settlement Agreements also state that the Non-Opioid Remediation Use Reports shall be available to the public. If you want access to these Reports, click here. The deadline for Settling States and Participating Subdivisions/Participating Special Districts to submit Non-Opioid Remediation Use Reports for any funds not used for Opioid Remediation through June 30, 2024 is September 30, 2024. The Directing Administrator will update this page on a rolling basis as these Reports are received.

The Directing Administrator of the Distributor Settlement Agreement, dated as of July 21, 2021; the Janssen Settlement Agreement, dated as of July 21, 2021; the CVS Settlement Agreement, dated as of December 9, 2022; the Walgreens Settlement Agreement dated as of December 9, 2022; the Walmart Settlement Agreement dated as of November 14, 2022; the Allergan Settlement Agreement dated as of November 22, 2022; and the Teva Settlement Agreement dated as of November 22, 2022 (together, the “Settlement Agreements”) created a dashboard available to the public reflecting both current and projected allocations available to the Settling States and Participating Subdivisions pursuant to the Settlement Agreements. This public dashboard is available here.